Dupilumab in the Treatment of Severe Atopic Dermatitis Refractory to Systemic Immunosuppression: Case Report
January 2019
in “
Einstein (São Paulo)
”
TLDR Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
In 2019, a case report demonstrated the successful use of Dupilumab, a monoclonal antibody targeting interleukin 4 and 13 receptors, in treating a patient with severe atopic dermatitis who didn't respond to two immunosuppressive agents, cyclosporine A and mycophenolate mofetil. The patient was given an initial dose of 600mg of Dupilumab subcutaneously, followed by 300mg every other week. After four doses, the patient's condition and quality of life significantly improved without any reported side effects, suggesting Dupilumab's potential effectiveness in treating severe atopic dermatitis resistant to immunosuppressive agents.
